Ribociclib plus letrozole in patients with hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC): Expanded safety analysis of the phase IIIb CompLEEment-1 trial

被引：0

作者：

Lu, Janice ^{[1
]}

Cottu, Paul ^{[2
]}

Martin, Miguel ^{[3
]}

Zamagni, Claudio ^{[4
]}

Prat, Aleix ^{[5
]}

Chia, Stephen ^{[6
]}

Jerusalem, Guy ^{[7
]}

Rajappa, Senthil ^{[8
]}

Timcheva, Constanta ^{[9
]}

Zhukova, Lyudmila ^{[10
]}

Zhou, Katie ^{[11
]}

Wu, Jiwen ^{[11
]}

Menon-Singh, Lakshmi ^{[11
]}

De Laurentiis, Michelino ^{[12
]}

机构：

[1] USC Norris Comprehens Canc Ctr, Los Angeles, CA USA

[2] Curie Inst, Paris, France

[3] Gregorio Maranon Gen Univ Hosp, Madrid, Spain

[4] St Orsola Malpighi Polyclin, Bologna Univ Hosp, Bologna, Italy

[5] Univ Barcelona, Hosp Clin, Barcelona, Spain

[6] Univ British Columbia, Vancouver, BC, Canada

[7] Univ Liege, CHU Liege, Liege, Belgium

[8] Basavatarakam Indo Amer Canc Hosp & Res Inst, Hyderabad, Telangana, India

[9] MHAT Nadezhda, Sofia, Bulgaria

[10] Loginov Moscow Clin Sci Ctr, Moscow, Russia

[11] Novartis Pharmaceut, E Hanover, NJ USA

[12] Natl Canc Inst Pascale Fdn, Naples, Italy

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PS10-05

引用

页数：1